Atopic Dermatitis — Going Beyond the Pill
Published in Pharma Exec April 2018 by Mariel Metcalfe
Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring for children with the disease. It also puts a considerable burden on healthcare resources. AD affects up to 20% of children and around 3% of adults worldwide and its prevalence is still increasing, especially in some lower income countries in Asia and Latin America. The majority of patients start to experience symptoms before they reach 5 years of age and often suffer from asthma or other allergies. Severity varies widely – some people might just suffer from a light rash on a few areas of the body and might get better as they get older, whilst others can suffer from very dry, bleeding and sore skin all over, with regular painful flare-ups, which continue into adulthood. In the US, physicians typically use the Body Surface Index to assess severity of the disease. Around 65% of patients in the US are recognised as suffering from moderate-severe eczema. Severe patients can suffer from more than 15 flare-ups per year, lasting two weeks or more.
Research Partnership and Janssen are 2017-18 BOBI Awards finalists
We are delighted to announce that an entry submitted by Research Partnership with Janssen has been selected as a finalist in the Best Business Impact category at this year’s BOBI (Best of Business Intelligence) Awards for our combined work in helping to reverse the fortunes of one of their established products, which up until recently had been suffering from declining market growth in the UK.
Portfolio analysis: Making Go/No-Go decisions to optimise the portfolio
When a pharma company is either considering acquiring a new agent, or developing one in-house, marketers need to understand the impact on the overall portfolio and decide whether to make a go or no-go decision on that asset.
PMRC New Jersey round up 2018
Earlier this month, Directors Tom Nolte and Melinda Shorr attended the Pharmaceutical Market Research Conference in Newark, New Jersey
Earlier this month, Directors Tom Nolte and Melinda Shorr attended the Pharmaceutical Market Research Conference in Newark, New Jersey, they presented the paper, ‘Portfolio Analysis: Optimizing Communication Approaches for Multiple Assets in a Category’. In their presentation they discussed how communications can be optimized in a portfolio, such as when multiple agents are being presented during the same rep detail or as a part of a digital strategy in a given category.
Good intentions, bad habits: Reforming mental healthcare in Latin America and the Caribbean
Published in eyeforpharma April 2018 by Marc Yates
The Latin America and Caribbean (LAC) region is a vast patchwork of countries, cultures and ethnicities, with a total population of more than 645 million, ranging from 209 million-plus in Brazil to islands with fewer than 100,000 inhabitants. The diversity is also economic. Recent years have seen marked improvements in income distribution and a burgeoning middle class, particularly in countries such as Argentina, Bolivia, Ecuador, Peru and Nicaragua. Yet Latin America and the Caribbean remains the region with the highest levels of income inequality worldwide. All of this has a significant bearing on the state of mental health in Latin America, where good intentions and genuine progress in reforming infrastructure and attitudes are clouded by treatment gaps, inadequate funding, over-centralisation, meagre human resources and persistent stigmatisation.